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AbstrAct
MicroRNA (miRNA) dysfunction is associated with a variety of human diseases, 
including cancer. Our previous study showed that miR-671-5p was deregulated 
throughout breast cancer progression. Here, we report for the first time that 
miR- 671- 5p is a tumor-suppressor miRNA in breast tumorigenesis. We found that 
expression of miR-671-5p was decreased significantly in invasive ductal carcinoma 
(IDC) compared to normal in  microdissected formalin-fixed, paraffin-embedded 
(FFPE) tissues.  Forkhead Box M1 (FOXM1), an oncogenic transcription factor, 
was predicted as one of the direct targets of miR-671-5p, which was subsequently 
confirmed by luciferase assays. Forced expression of miR-671-5p in breast cancer 
cell lines downregulated FOXM1 expression, and attenuated the proliferation and 
invasion in breast cancer cell lines. Notably, overexpression of miR-671-5p resulted in 
a shift from epithelial-to-mesenchymal transition (EMT) to mesenchymal-to-epithelial 
transition (MET) phenotypes in MDA-MB-231 breast cancer cells and induced S-phase 
arrest. Moreover, miR-671-5p sensitized breast cancer cells to cisplatin, 5-fluorouracil 
(5-FU) and epirubicin exposure. Host cell reactivation (HCR) assays showed that 
miR- 671-5p reduces DNA repair capability in post-drug exposed breast cancer cells. 
cDNA microarray data revealed that differentially expressed genes when miR-671- 5p 
was transfected are associated with cell proliferation, invasion, cell cycle, and EMT. 
These data indicate that miR-671-5p functions as a tumor suppressor miRNA in 
breast cancer by directly targeting FOXM1. Hence, miR-671-5p may serve as a novel 
therapeutic target for breast cancer management.
IntroductIon
The human genome is composed of approximately 
1.5% protein-coding genes, with the rest being non-coding 
[1]. Biological functions of the non-coding genome have 
been widely investigated in recent years. microRNAs 
(miRNAs) are a class of evolutionary conserved, non-
coding RNAs, 18–25 nucleotides in length, that regulate 
gene expression by annealing to their complementary sites 
on coding sequences (CDS) or 3′ untranslated regions 
(UTRs) of target genes [2]. Due to their stability and size, 
miRNAs can be readily extracted from Formalin-Fixed, 
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Paraffin-Embedded (FFPE) samples [3], or circulating 
blood as stable biomarkers for cancer detection. miRNA-
based anticancer therapies have recently been explored, 
either alone or in combination with current targeted 
therapies [4]. miRNAs could serve as novel diagnostic 
and prognostic candidates, as well as potential therapeutic 
targets. For example, we recently reported that miR-
638 may serve as a potential novel microRNA for triple 
negative breast cancer (TNBC) treatment [5]. Deregulated 
miRNA expression profiles were identified in many human 
cancers [6] including breast cancer [7]. 
The commonly accepted model of human breast 
cancer proposes a linear multistep process which initiates 
as flat epithelial atypia (FEA), progresses to atypical 
ductal hyperplasia (ADH), evolves into ductal carcinoma 
in situ (DCIS), and culminates in the potentially lethal 
stage of invasive ductal carcinoma (IDC) [8]. This linear 
model of breast cancer progression has been the rationale 
for detection methods such as mammography in hopes of 
diagnosing and treating breast cancer at earlier clinical 
stages [9]. Breast cancer diagnosis and treatment results 
are currently heavily dependent on timeframe of detection 
and responsiveness to chemical treatment. Recent studies 
have shown that miRNAs could be important in breast 
cancer early detection as they become aberrantly expressed 
during tumorigenesis. Some miRNAs exhibit distinct 
functions in TNBC as compared to non-TNBC tumors. 
TNBC is known as ER-negative, PR-negative, and HER- 2 
negative subtype of breast cancer, which is insensitive to 
some of the most effective therapies available for breast 
cancer treatment including HER2 and endocrine therapies.
Our previous study compared miRNA expression 
profiles in archived microdissected FFPE components, such 
as normal, ADH, DCIS, and IDC, within the same tumor 
sample [3]. We found that one of the miRNAs, miR-671-5p, 
was consistently down-regulated in ADH and IDC compared 
to normal [3]. miR-671-5p dysfunction is associated with 
a few human cancers [10], but there is no report in breast 
cancer. Here, we identified miR-671- 5p as a tumor-suppressor 
miRNA by targeting Forkhead Box M1 (FOXM1), an 
oncogenic transcription factor, in breast tumorigenesis. 
results
Attenuated expression of mir-671-5p in breast 
cancer progression
In our previous work miR-671-5p was observed to 
be downregulated in FFPE tissues during breast cancer 
progression. To further investigate expression of miR-
671-5p in breast cancer progression, we analyzed miR-
671-5p (Acc#: MIMAT00038800) expression in a separate 
cohort including 30 breast cancer samples microdissected 
into normal and cancer cells from the FFPE tissue by 
qRT-PCR. Downregulation of miR-671-5p expression 
was present in 21 of 30 (70%) IDCs compared with their 
adjacent tissues (p < 0.05), which includes 8 of 10 TNBCs 
(80%) and 11 of 20 (60%) non-TNBCs (Figure 1). These 
results suggest the dynamic expression changes of miR-
671-5p may be frequent events during the progression of 
breast cancer. 
mir-671-5p target gene prediction
FOXM1, a member of the FOX superfamily of 
transcription factors, was one of the 7304 predicted target 
genes of miR-671-5p by MICRORNA. FOXM1 has been 
implicated to play a role in cell proliferation [11], cell cycle 
control [12], DNA damage and repair, tumor development 
and progression [13], and chemotherapy [14]. As such, we 
chose to focus on the regulatory role of miR-671-5p on 
FOXM1. 
mir-671-5p regulates FoXM1 expression in 
breast cancer
To validate the computational predictions and the 
biological effects of miR-671-5p targeting FOXM1, we 
first examined the expression of miR-671-5p and FOXM1 
in breast cancer cell lines. We found that the level of 
miR-671-5p was inversely related to FOXM1 expression 
(Figure 2A). 
To confirm the specificity of miR-671-5p targeting 
FOXM1, we performed luciferase reporter assays with 
pEZX-MT05 vectors containing the miR-671-5p binding 
site (either wild type or mutant sequences) in the FOXM1 
3’UTR region and DNA with pEZX-miR-671-5p or 
pEZX-scrambled control (Figure 2B). After successful 
co-transfection of the plasmids containing miR-671-5p 
and FOXM1 3′UTR wild type sequence into breast cancer 
cells, luciferase activities were significantly decreased in 
miR-671-5p transfected MDA-MB-231 cells compared 
with the cotransfection of those containing either miR-
671-5p /FOXM1 3’UTR mutant sequence or scrambled 
control/ FOXM1 3’UTR wild type sequence. Decreased 
luciferase activity was also observed in miR-671-5p/ 
FOXM1 3’UTR wild type cotransfected in Hs578T and 
MCF-7 cells, although the differences were not statistically 
significant (Figure 2C). Our data suggest that miR-671- 5p 
specifically targets the 3′UTR region at 828- 848 nt of 
FOXM1 (Acc# XM_005253676.2). Consistent with the 
luciferase assay results, significant down-regulation 
of FOXM1 mRNA was observed in MDA-MB-231, 
Hs578T, and SKBR3 cells after overexpression of miR-
671-5p. Decreased expression of FOXM1 mRNA was 
also observed in miR-671-5p transfected MCF-7 and 
T47D cells, although the change was not statistically 
significant (Figure 3A). Immunofluorescence staining and 
Western blot analyses showed decreased FOXM1 protein 
expression in miR-671-5p transfected cells compared with 
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the mock control in both MDA-MB-231 and MCF-7 cell 
lines (Figure 3B and 3C). These results suggest that miR-
671-5p directly regulates FOXM1 expression by binding 
to its 3′UTR in breast cancer. 
overexpression of mir-671-5p inhibited breast 
cancer cell proliferation and invasion
We have demonstrated that miR-671-5p suppressed 
FOXM1 expression on both the mRNA and protein levels. 
FOXM1 is a typical proliferation-associated transcription 
factor [11]. To determine if overexpression of miR-671-5p 
affects cell proliferation, we transfected miR-671-5p mimic 
to breast cancer cell lines and examined proliferation via 
MTT assays. Overexpression of miR-671- 5p resulted 
in significantly reduced FOXM1 expression in protein 
level (Figure 4A) and decreased proliferation (Figure 4B) 
compared with the mock control. Conversely, transfection 
of miR-671-5p inhibitor resulted in increased cell growth 
in all cell lines. These results indicate an anti-proliferative 
effect of miR-671-5p in breast cancer cells. 
FOXM1 has been shown to promote tumor cell 
invasion [15]. Using the BD Matrigel, we found that miR-
671-5p overexpression exhibited significant inhibition 
of invasion in MDA-MB-231 cells (60%) and moderate 
inhibition in Hs578T and SKBR3 cells (40%) compared 
to the mock (Figure 4C). For non-TNBC cell lines MCF-7 
and T47D the change in invasion was not as significant 
as in TNBC cell lines MDA-MB-231 Hs578T and 
SKBR3. Conversely, transfection of miR-671-5p inhibitor 
promoted cell growth in all cell lines except MCF-7 cells. 
These results suggest that miR-671-5p might play a greater 
role in TNBC cell lines than in non-TNBC cell lines. 
mir-671-5p induced s-phase cell cycle arrest 
Due to the role of FOXM1 in cell cycle [12], we 
sought to examine the effects of miR-671-5p in cell 
cycle regulation. miR-671-5p stable transfected MDA-
MB-231 cells were labeled with PI and analyzed by 
DNA flow cytometry. Transfection of miR-671-5p into 
MDA-MB-231 cells (Figure 5A) caused an S-phase 
cell cycle arrest and a corresponding decrease in the 
G1 phase of the cells (Figure 5B). Because CCNB1 is a 
downstream target of FOXM1, we investigated whether 
the G2- phase cyclin, CCNB1 [16], was affected by miR-
671-5p expression. We found that CCNB1 expression was 
decreased in MDA-MB-231 as expected (Figure 5B and 
Supplementary Figure 1A). These findings suggest that 
miR-671-5p regulates cell cycle via FXOM1 mediated 
CCNB1 repression. 
mir-671-5p inhibits epithelial to mesenchymal 
transition (eMt)
EMT has recently been linked to cancer stem cell 
phenotypes [17] [18]. MDA-MB-231 cell line displays an 
elongated and a highly invasive, metastatic mesenchymal 
phenotype [19] [20]. We observed that mock transfected 
MDA-MB-231 exhibits the same mesenchymal shape as 
the parental MDA-MB-231 cells (elongated, irregular 
fibroblastoid morphology), while miR-671-5p transfected 
MDA-MB-231 cells reversed to the epithelial shape 
(rounded). On the contrary, a converse result was observed 
after miR-671-5p knockdown by transfection of miR-
671-5p inhibitor in the stable transfected cells (Figure 5C, 
top). We next aimed to determine whether it was possible 
Figure 1: expression of mir-671-5p in Idc vs. adjacent normal. Black bars depict TNBCs while gray bars are for non-
TNBCs, in comparison to the normal in white. Down-regulation of miR-671-5p expression was present in 21 of 30 (70%) of IDC 
compared with their adjacent normal tissue (p < 0.05). 
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for the mesenchymal-like MDA-MB-231 breast cancer 
cells to undergo MET following expression of miR-
671- 5p. Consistent with this notion, immunofluorescence 
(Figure 5C, middle) and Western blot (Figure 5C, bottom) 
analyses revealed an upregulation of the epithelial 
marker E-cadherin and a concomitant reduction in the 
EMT marker vimentin in miR-671-5p transfected MDA-
MB-231 cells. The converse E-cadherin and vimentin 
expression was observed with the transfection of miR-
671- 5p inhibitor in the stable transfected cells. These 
findings suggest that miR-671-5p reversed the EMT 
phenotype to a predominantly epithelial phenotype. 
Therefore miR-671-5p could be a therapeutic target for 
breast cancer metastasis.
Forced expression of FoXM1 rescued cell 
proliferation, invasion and eMt in mir-671-5p-
stable-transfected cells
To confirm miR-671-5p inhibits proliferation, 
invasion and EMT by directly regulating FOXM1, miR-
671-5p/mock-stable-transfected MDA-MB-231 cell lines 
were transiently transfected with pcDNA3.1-FOXM1 or 
pcDNA3.1 control. After pcDNA3.1-FOXM1 transiently 
transfection, increased proliferation capability was 
detected in mock-stable-transfected MDA-MB-231, while 
a slight increase in proliferation was observed in miR-
671-5p-stable-transfected MDA-MB-231 cells, compared 
to the pcDNA3.1 empty vector control (Supplementary 
Figure 1A). We proposed that both endogenous and 
exogenous FOXM1 was suppressed in miR-671-5p-stable-
transfected MDA-MB-231 cells. Our data suggesting 
that restoration of FOXM1 abolished the inhibition 
of proliferation by miR-671-5p. In consistent with 
proliferation capability, Matrigel invasion assays revealed 
that restoration of FOXM1 abolished the inhibition of 
invasion capabilities of miR-671-5p in stable-transfected 
MDA-MB-231 cells (Supplementary Figure 1B). Western 
blotting analysis showed that overexpression of FOXM1 
can restore the EMT marker vimentin and decreased 
epithelial marker E-cadherin in protein level by miR-
671- 5p (Supplementary Figure 1C). These results suggest 
that miR-671-5p functions as a tumor suppressor by 
directly targeting FOXM1.
Figure 2: mir-671-5p targets FoXM1 in breast cancer cell lines. (A) Inverse correlated expression of miR-671-5p and its target 
FOXM1 in breast cancer cell lines. (b) Location of the miR-671-5p binding site at the 3′-UTR of FOXM1 corresponding to the miR-671-5p 
sequence. (c) Relative luciferase activity was measured in breast cancer cell lines co-transfected with 100 ng of DNA with pEZX-miR-671-5p 
or pEZX-scrambled control (mock), and 100 ng of pEZX-MT05-FOXM1 (wild type or mutant) by FuGENE reagent (Promega) for 48 h. 
The data were reported as mean ± S.D. for three independent experiments (*p < 0.05).
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overexpression of mir-671-5p sensitizes MdA-
Mb-231 to chemotherapy and uV treatment
FOXM1 has been found to be overexpressed in 
TNBC [14] and has been suggested as a critical mediator 
of sensitivity and resistance to anticancer drugs, such as 
cisplatin, 5-FU and epirubicin [21] [14, 22]. Furthermore, 
FOXM1 has been reported to respond to DNA damage 
caused by IR (Infrared Radiation) or UV irradiation [23]. 
Based on our data, we reasoned that overexpression of 
miR-671-5p could sensitize cells to chemotherapeutic 
agents or UV treatment by downregulating FOXM1. 
Figure 3: mir-671-5p negatively regulates FoXM1 expression in breast cancer cell lines. (A) qRT-PCR analysis of 
miR-671-5p and FOXM1 mRNA expression in breast cancer cell lines transfected with miR-671-5p mimic or mock (**p < 0.01, *p < 0.05). 
(b) Immunofluorescence analysis of FOXM1 protein expression in MDA-MB-231 cells transfected with miR-671-5p or mock. (c) Western 
blotting analysis of FOXM1 expression in breast cancer cell lines. FOXM1 expression was decreased more significantly in MDA-MB-231 
(71%) and MCF-7 (60%) cells in comparison with SKBR3 (23%) cells when miR-671-5p was overexpressed. 
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To evaluate this hypothesis, we treated miR-671-5p 
transfected stable MDA-MB-231 cells with cisplatin, 
5-FU, epirubicin, and UVC. Chemo/UV sensitivity was 
determined by the MTT assay. As shown in Figure 6, cells 
were treated with anticancer drugs and UVC in different 
time or dose intervals. miR-671-5p overexpression 
significantly increased cell sensitivity to cisplatin, 5-FU, 
and epirubicin in MDA-MB-231 cells compared to mock 
transfected lines. Repression of miR-671-5p expression 
by miR-671-5p inhibitor resulted in a converse effect. 
However, a significant sensitivity was detected only after 
48 h of UV exposure in miR-671-5p transfected MDA-
MB-231 cells. These results suggest that miR-671-5p might 
be able to reverse anticancer resistance through inhibition 
of FOXM1 as a new therapeutic target for breast cancer. 
miR-671-5p overexpression significantly reduced 
post-uV/drug host cell reactivation activity 
FOXM1 has been implicated in mediating drug 
resistance in breast cancer by enhancing DNA repair [14]. 
We then asked whether miR-671-5p enhanced the 
sensitivity of breast cancer cell lines to chemotherapy via 
DNA repair pathway. We measured luciferase activity by 
transfecting pCMU-Luc vector, which was pre-treated by 
anticancer drugs and UVC, into miR-671-5p transfected 
stable MDA-MB-231 cells respectively. We found that 
miR-671-5p transfected stable MDA-MB-231 cells 
exhibited significantly reduced DNA repair capability 
compared to the mock-transfected cells. Our results 
Figure 4: mir-671-5p inhibits proliferation and decreases invasive ability of breast cancer cell lines. (A) FOXM1 
protein expression was examined by Western blot after transfection of miR-671-5p mimic and inhibitor. (b) Effects of miR-671-5p on cell 
proliferation were determined by MTT assays. Proliferative activity was decreased after transfection of miR-671-5p mimic and increased 
after transfection of miR-671-5p inhibitor compared to the mock control in breast cancer cell lines. Values represent the mean ± S.D. for 
three independent experiments (**p < 0.01, *p < 0.05). (c) Transwell assays with Matrigel were performed for the invasion activity of 
breast cancer cells transfected with either miR-671-5p mimic or the mock control. Overexpression of miR-671-5p significantly reduces 
cell invasion in MDA-MB-231, Hs578T and SKBR3, but only slightly in MCF-7 and T47D. Invasion ability of the cells was displayed 
as a percentage of the absolute cell number (bottom). Results are displayed as mean data ± SE (**p < 0.01, *p < 0.05). Five fields of unit 
area on each membrane or whole membrane were counted for cell numbers, and the experiments were repeated three times in triplicate.
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demonstrate that miR-671-5p plays an important role in 
DNA repair by targeting FOXM1, which enhances the 
sensitivity of anticancer drugs in breast cancer cells.
mir-671-5p overexpression induces global gene 
expression profile changes 
To fully examine the effect of miR-671-5p on 
global gene regulation, we performed microarray analyses 
to identify targets experimentally by comparing miR-
671- 5p transfected and mock transfected breast cancer cell 
lines, MDA-MB-231, SKBR3 and MCF-7. The data was 
deposited in GEO database (Acc# GSE62411). In MDA-
MB-231 cell line, a total of 81 genes were differentially 
expressed (Supplementary Figure 2, Supplementary 
Table 1; t test, p < 0.05, fold-change ≥  1.5), including 
24 up- and 57 down-regulated genes. This is consistent 
with our results above, where FOXM1 and CCNB1 were 
significantly downregulated in miR-671-5p transfected 
MDA-MB-231 cells compared with mock-transfected 
cells. In addition, genes associated with cell proliferation, 
invasion, cell cycle, and EMT were detected to be 
downregulated in miR-671-5p transfected MDA-MB-231 
cells, such as GINS Complex Subunit 2 (GINS2), cyclin-
dependent kinase 2 (CDK2), and minichromosome 
maintenance complex component 10 (MCM10) gene. 
In SKBR3 cell line, we found 117 genes that were 
differentially expressed (Supplementary Figure 1, t test, p < 
0.05, fold-change ≥ 1.5), including 55 up- and 62 down-
regulated. In MCF-7 cell line, 64 genes were differentially 
expressed (Supplementary Figure 1, t test, p < 0.05, fold-
change ≥ 1.5), 40 up- and 24 down-regulated.
Figure 5: mir-671-5p induces s-phase arrest and inhibits eMt. (A) Schematic diagram of miR-671-5p precursor sequence in 
pEZX-MR04. (b) Overexpression of miR-671-5p (top) induces S-phase arrest by flow cytometry (middle) and downregulated CCNB1 
expression (bottom) in miR-671-5p stable transfected MDA-MB-231 cells when compared with mock transfected cells using Western blot 
analysis. (c) Overexpression of miR-671-5p shifts MDA-MB-231 cells from EMT to MET phenotype. Top panel showing cell morphology 
was observed by microscopy in MDA-MB-231 cells transfected with mock and miR-671-5p. Mock transfected MDA-MB-231 cells 
displayed elongated, irregular fibroblastoid morphology whereas miR-671-5p transfected cells showed a more epithelioid appearance. The 
middle panel shows immunofluorescence staining of E-cadherin and vimentin in the indicated cells. The bottom panel shows the Western 
blot analysis of E-cadherin and vimentin protein levels in indicated cells.
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dIscussIon
MiRNAs have been shown to play important 
roles in carcinogenesis. Thus far only a limited number 
of studies have investigated miR-671-5p [10], [24, 25]. 
We report a previously undescribed mechanism for the 
tumor suppressor role of miR-671-5p in breast cancer. We 
showed that miR-671-5p: 1) was downregulated in breast 
cancer; 2) suppressed proliferation and invasion of breast 
cells by targeting FOXM1; 3) inhibited EMT and induced 
S-phase arrest; and 4) sensitized breast cancer cells to 
cisplatin, 5-FU and epirubicin treatment by impairing 
DNA repair capability. Thus, miR-671-5p appears to be a 
novel therapeutic target for breast cancer treatment. 
mir-671-5p serves as a tumor suppressor in 
human breast cancer progression by targeting 
FoXM1 
To date, aberrant expression of miR-671-5p has 
been detected in hepatocellular carcinoma [25], lung 
cancer [10], and epithelioid sarcoma [26]. In addition, 
miR-671-5p has been showed to silence the SMARCB1 
expression in epithelioid sarcoma [26] and to repress 
Figure 6: effect of mir-671-5p on sensitivity of breast cancer cell lines to uVc/ chemosensitivity. miR-671-5p or mock 
was stable transfected into MDA-MB-231 cell line. The stable transfected MDA-MB-231 cell line was further transfected with miR-671-5p 
inhibitor or mock. Cells were treated by cisplatin, 5-FU, epirubicin and UVC respectively. Cell sensitivity was measured by MTT assays. 
miR-671-5p overexpression significantly increased cell sensitivity to cisplatin, 5-FU and epirubicin. Results are displayed as mean data 
± SE. **p < 0.01 and *p < 0.05 are considered statistically significant with comparison to the mock.
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BCL2L12 expression in melanoma [24]. In our present 
work, we found that miR-671-5p was downregulated in 
breast cancer progression, and forced expression of miR-
671-5p inhibited cell proliferation and invasion in breast 
cancer cell lines. Our results demonstrated that miR-
671-5p is a potential tumor suppressor miRNA in breast 
oncogenesis. 
We showed that FOXM1 is a novel target of miR-
671-5p and that overexpression of miR-671-5p can 
downregulate FOXM1. FOXM1 is a member of the FOX 
superfamily of transcription factors. FOXM1 exerts crucial 
role in a wide range of biological processes [27], including 
as a human proto-oncogene [28] involved in metastasis 
[29] and proliferation [30]. Unlike other Fox-transcription 
factors, FOXM1 is associated with cell proliferation and 
is expressed only in proliferating cells [31–32]. We further 
found that forced expression of miR-671-5p in breast 
cancer cell lines resulted in FOXM1 down-regulation and 
significant proliferation and invasion inhibition, which 
implicates a tumor suppressor function of miR-671-5p by 
targeting FOXM1. In addition to FOXM1, our microarray 
data (Supplementary Figure 1) showed reduced expression 
of cell proliferation associated genes such as CDK2, 
GINS2, and MCM10 (Figure 7 and Supplementary Figure 
1A) in miR-671-5p transfected MDA-MB-231 cells. We 
analyzed the relationship between FOXM1 and these 
genes by searching published data and bioinformatics 
information (http://itfp.biosino.org/itfp/). We found that 
CDK2, GINS2, and MCM10 are downstream genes of 
FOXM1 [33, 34]. Thus, we reasoned that the inhibited 
proliferation and invasion by miR-671- 5p is due to 
suppressed FOXM1 expression and/or its downstream 
target genes (Figure 7). 
Notably, silencing FOXM1 expression by 
miR- 671- 5p in SKBR3 and MCF-7 cells inhibited their 
proliferation and invasion, but not as significantly as in 
MDA-MB-231cells. This suggests that miR-671-5p might 
play a greater role in TNBC than in non-TNBC cells 
(Figures 3 and 4). 
mir-671-5p regulates cell cycle progression in 
human breast cancer cells 
FOXM1 has been demonstrated as a key cell 
cycle regulator [27, 35, 36], which activates expression 
of the cell cycle genes required for both S and M 
phase progression [37]. However, detailed molecular 
mechanisms that control the level of FOXM1 during 
cell cycle progression remains elusive. In our study, we 
Figure 7: A schematic model for the regulation of mir-671-5p. miR-671-5p directly targets FOXM1. Down-regulation of 
FOXM1 could 1) inhibit GINS2 and promote cell proliferation; 2) inhibit CDK2 and enhance cell invasion and induce S-phase arrest; 
3) inhibit CCNB1 to induce S-phase arrest; 3) inhibit MCM10 which is involved in S-phase arrest and EMT; 4) inhibit CCNB1 to induce 
S-phase arrest; 5) affect DNA repair gene(s) to function in chemotherapy.
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observed that the S-phase arrest in miR-671-5p transfected 
cells is associated with downregulation of FOXM1 and 
CCNB1. CCNB1 is essential for the initiation of mitosis. 
Thus, reduced CCNB1 expression could explain the 
ability of miR-671-5p for S-phase arrest and inhibition of 
G2-phase entry. In addition, inhibition of CDK2 has been 
associated with S-phase arrest [38] [39]. We detected 
significant downregulation of CDK2 expression in miR-
671-5p transfected cells. Our data indicates that miR-671-
5p may regulate cell cycle via FOXM1 mediated CCNB1 
and/or CDK2 downregulation (Supplementary Figure 1). 
mir-671-5p plays an essential role in tumor 
suppression by inducing a shift from eMt to 
Met 
Studies suggest that a round cellular morphology 
supports a less stiff cytoskeleton configuration compared 
with flat cellular morphology [40]. Bao et al reported 
that overexpression of FOXM1 led to mesenchymal 
phenotype, while inhibited FOXM1 expression by miR-
200b caused reversal of EMT phenotype in pancreatic 
cancer cells [41]. In our study, we observed that miR-
671-5p transfected MDA-MB-231 cells showed an 
epithelioid appearance and expressed epithelial cell 
marker E-cadherin, while mock transfected cells 
displayed elongated, irregular fibroblastoid morphology 
and expressed typical mesenchymal marker vimentin, 
suggesting a tumor suppressive effect of miR-671-5p 
in EMT. It has been well documented that induction of 
EMT was associated with aggressive characteristics, 
such as cell attachment, migration, and invasion. We 
found that miR-671-5p transfected MDA-MB-231 
cells have a significantly decreased number of invasive 
cells. Interestingly, we found that overexpression of 
miR-671- 5p resulted in not only reduced expression 
of FOXM1, but also the MCM10 gene (Figure 7 and 
Supplementary Figure 1A). MCM10 is a nuclear DNA 
binding protein and a predicted downstream target of 
FOXM1. Chattopadhyay et al reported that MCM10 
depletion by siRNA showed a similar cell morphological 
change to miR-671-5p transfected cells. Furthermore, 
they found that MCM10 depletion inhibited proliferation 
and affected cell cycle progression [42]. Our data indicate 
that the shift from EMT to MET is due to miR-671-5p 
mediated downregulation of FOXM1 and MCM10. The 
exact mechanism warrants further investigation. 
mir-671-5p sensitized breast cancer cells to 
anticancer drugs 
Clinically, 5-FU and epirubicin are commonly used 
drugs for breast cancer treatment, particularly 5-FU for 
TNBC [43] [44]. Cisplatin is a chemotherapeutic agent 
not routinely used for breast cancer treatment. However, 
it was reported that single-agent cisplatin could induce 
a response in TNBC patients [45]. Chemotherapy 
resistance and healthy tissue damage are major problems 
in cancer treatment. Therefore, identifying specific 
molecular targets in cancer therapy is essential. A recent 
study has revealed that miR-671-5p was associated 
with chemoradiotherapy [46]. Furthermore, FOXM1 is 
implicated in drug resistance of genotoxic induction, but 
its mechanism of action remains elusive. We found that 
miR-671-5p overexpression resulted in downregulated 
FOXM1, and further demonstrated miR-671-5p can 
sensitize breast cancer to anticancer drugs. Our present 
results implicate the potential effects of miR-671-5p on 
chemotherapy by regulating FOXM1.
DNA repair activity plays a critical role in 
therapeutic resistance. Nucleotide excision repair (NER) 
is responsible for the repair of bulky DNA lesions 
induced by UV and anticancer drugs. Cisplatin, 5-FU, 
and epirubicin induced DNA damage is primarily repaired 
via the NER [47] [48] [49]. HCR assay is applicable for 
the analysis of different DNA repair systems. To address 
the mechanism of miR-671-5p improving the sensitivity 
of anticancer drugs and UV irradiation, we evaluated 
the DNA repair activity by HCR. We observed that 
overexpression of miR-671-5p impaired DNA repair in 
breast cancer cell lines, suggesting that miR-671-5p might 
correspond to the cellular stress upon radiation and DNA 
damage agents. 
Our data, for the first time, defined a role for miR-
671-5p as a tumor suppressor miRNA in breast cancer, 
involving cell proliferation, invasion, cell cycle arrest, 
EMT, and chemotherapeutic sensitivity by directly 
targeting FOXM1 and its downstream genes. Therefore, 
miR-671-5p may serve as a novel therapeutic target in the 
management of breast cancer, particularly for TNBC. 
MAterIAls And Methods
breast cancer cell lines and cell culture
The human breast cancer cell lines, MDA-MB-231, 
Hs578T, SKBR3, BT-20, MDA-MB-468, MCF-7, and 
T47D were purchased from ATCC (American Type 
Culture Collection) and cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) (Lonza) supplemented 
with 10% fetal bovine serum and 1% penicillin and 
streptomycin antibiotics. Immortalized MCF-10A cells 
were cultured in MEGM medium (CC-3150, Lonza) 
containing 100 ng/ml of cholera toxin to make a complete 
growth culture medium. All cell lines were grown in a 
37°C humidified incubator with 5% CO2. 
FFPe breast cancer tissue microdissection
The FFPE tissue blocks were retrieved from 
the tissue repository of the Armed Forces Institute of 
Pathology (AFIP) with its IRB (Internal Review Board) 
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approval. This study was approved by the IRB of the 
George Washington University. FFPE breast tissues from 
breast cancer patients were microdissected for the purpose 
of confirming the expression level of miRNA-671-5p in 
ADH, DCIS, and IDC as compared to normal tissue. 
bioinformatics analysis and target prediction
The online software program from the website 
www.microRNA.org was used for bioinformatics analysis 
and target prediction of miRNAs.
dual luciferase reporter assay 
Cells were plated (7 × 105 cells/well) in 24 well 
plates and co-transfected with 100 ng of DNA with pEZX-
FOXM1-3′UTR (wild type and mutant) expression clones 
inserted downstream of the firefly luciferase gene and 
100 ng of DNA with pEZX-miR-671-5p or the pEZX-
scrambled control (mock), using FuGENE Transfection 
Reagent (Promega). An independently-controlled Renilla 
luciferase gene was used as normalization control. 
Luciferase activities were determined with the Dual-
Luciferase Reporter System (GeneCopoeia). Each sample 
was measured in triplicate using Glomax (Promega, 
Madison, WI). Firefly luciferase activity was normalized 
to Renilla luciferase expression for each sample.
transfection of mir-671-5p and FoXM1 in 
human breast cancer cell lines
Transient transfection was performed as described 
[5]. After overnight incubation, cells reached 30%–50% 
confluence, were transiently transfected with miR-671- 5p 
mimic (Cat# 4464066), mock (mirVana™ miRNA 
Mimic, Negative Control, Cat# 4464059), inhibitor 
(Cat# 4464084), and mock (mirVana™ miRNA Inhibitor, 
Negative Control, Cat# 4464077) (Lifetechnologies) by 
Lipofectamine RNAiMAX (Life Technologies) using the 
Opti-MEM Reduced Serum Medium (Life Technologies). 
Cells were subjected for further analysis after 24 h 
transfection. Stable transfections were done in 6-well 
plates, seeded with 250,000 cells. pEZX-MR05-miR-671 
containing the miR-671 precursor and pEZX-MR05-
control with a scrambled sequence was obtained from 
GeneCopoeia (Rockville, Maryland, USA), and transfected 
into MDA-MB-231 cell lines using the standard FuGENE 
HD transfection reagent. Media containing puromycin 
was applied 5 days post-transfection. Stable clones were 
generated by plating 5 cells/ml of media in each well of 
a 96-well plate. For rescue experiments, the pcDNA3.1-
FOXM1 plasmid containing full-length human FOXM1 
was a kind gift of Dr. Huang (MD Anderson Cancer 
Center‎). miR-671-5p/mock-stable-transfected MDA-
MB-231 cell lines were transiently transfected with 
pcDNA3.1-FOXM1 and pcDNA3.1 empty vector. Cell 
proliferation and invasion were examined by MTT assays 
and Matrigel invasion assays. EMT marker vimentin and 
epithelial marker E-cadherin were examined by Western 
blot assays.
rnA extraction and quantitative real-time reverse 
transcription-Pcr (qrt-Pcr)
FFPE and cell line total RNAs were isolated and 
quantitated. miR-671-5p expression was assayed by 
the Taqman MiRNA Reverse Transcript Kit (Applied 
Biosystems), and target gene expression was analyzed 
using the ABI 7300 System as described previously [3]. 
Primer sequences are available upon request.
Protein extraction and Western blot analysis
Proteins were extracted from cell lines using 
RIPA Buffer (Thermo) according to the manufacturer’s 
protocol. Protein extraction and western blot analysis 
with chemiluminescent detection were as described [50]. 
The following antibodies and dilution factors were used: 
FOXM1 rabbit polyclonal antibody (13147- 1- AP, 1:800, 
Proteintech), cyclin B1 (CCNB1) rabbit polyclonal 
antibody (4138P, 1:800, Cell Signaling), anti-rabbit 
vimentin (5741, 1:100 Cell Signaling), anti-rabbit 
E-cadherin (3195, 1:200, Cell Signaling), mouse GAPDH 
monoclonal antibody (MA5-15738, 1:2000, Sigma), anti-
rabbit IgG conjugated to horse radish peroxidase (7074S, 
1:2000, Cell Signaling), and anti-mouse IgG (7076S, 
1:2,000, Cell Signaling). 
Immunofluorescence assays
Cells were seeded at 2 × 104 cells per well on 
glass coverslips in six-well plates and fixed in 2% 
paraformaldehyde as described previously [5]. Confocal 
images were obtained using a LSM 510 Confocal 
microscope (Carl Zeiss). The number of nuclei containing 
at least one localized area of immunofluorescence was 
determined by examination of the confocal images. 
Antibodies for immunofluorescence assays used were as 
follows: FOXM1 rabbit polyclonal antibody (13147-1-AP, 
1:500, Proteintech) and BRCA1 (ab16780, 1:500, Abcam), 
anti-rabbit vimentin (5741, 1:100 Cell Signaling) and anti-
rabbit E-cadherin (3195, 1:200, Cell Signaling), Alexa 
Flour 568 goat anti-mouse IgG (1:500, Invitrogen), and 
Alexa Flour 568 goat anti-mouse IgG (1:500, Invitrogen).
Matrigel invasion assays 
Matrigel invasion assays were performed using 
the BD BioCoat™ Matrigel™ Invasion Chamber (BD 
Biosciences) as previously described [51]. Briefly, prior 
to the start of each experiment, 500 μl of warm (37°C) 
serum-free DMEM medium was added to the upper 
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and lower chambers and allowed to rehydrate for 2 h in 
a 37°C cell culture incubator while 8 × 104 cells were 
transfected by either miR-671-5p and inhibitor or their 
mocks and seeded onto the top chamber of pre-wetted 
inserts. Cells were incubated in an Matrigel chamber 
for 24 h. The invasive cells present were fixed, stained 
with the Diff-Quick staining solution and counted (five 
microscope fields under the 10X len). Experiments were 
done in duplicates for each cell line twice. Cell counts 
were performed on five non-overlapping random fields for 
each chamber and four chambers were counted for each 
experimental point, with the percentage of invasive cells 
being normalized to corresponding controls. 
cell cycle distribution analysis
PI staining was used to analyze DNA content. 
Stable transfected cells with miR-671-5p were plated at 
concentrations determined to yield 60–70% confluence 
within 24 h. Cells were harvested, and labeled with PI. 
Briefly, cells were resuspended in PBS, fixed with 70% 
ethanol, labeled with PI (0.05 mg/ml), incubated at room 
temperature in the dark for 30 min, and filtered through 
41-μm spectra/mesh nylon filters (Spectrum, Rancho 
Dominguez, CA). DNA content was then analyzed using 
the FACScan instrument equipped with FACStation 
running Cell Quest software (Becton Dickinson) at GW. 
All experiments were performed in duplicate and yielded 
similar results. 
chemosensitivity and Mtt assays
We first established the stable miR-671-5p or 
mock transfected cells, and then those cells were further 
transient-transfected with miR-671-5p inhibitor or 
inhibitor mock. Cells were washed with PBS. The MTT 
solution was added to each well and incubated at 37°C 
with 5% CO2 for 3 h, and removed and 100 μl DMSO was 
added to each well and incubated in a 37°C humidified 
incubator with 5% CO2 for 30 min. Color development 
was measured using a spectrophotometer at 570 nm on a 
plate reader (BIO-TEK Instruments) and quantified as per 
the manufacturer protocol (Promega, USA). To determine 
the drug effect after exposure, the miR-671-5p mimic or 
mock stable transfected MDA-MB-231 cells were seeded 
in 96-well tissue culture plates. Cells were treated with 
various concentrations of cisplatin (0.5 to 8 µg/mL), 
5-Fluorouracil (5-Fu), 2.5 to 20 nM), or epirubicin (50 to 
200 nM). MTT was added and absorbance was measured 
at different time points. 
Plasmid treatment with anticancer drugs/uV light 
and host cell reactivation assays
pCMVLuc reporter gene plasmid (a kind gift from 
Dr. Kenneth H. Kraemer, National Cancer Institute, NIH) 
was dissolved in 10 mm Tris-HCl, 1 mm EDTA, pH 8 
(TE buffer) to a final concentration of 100  μg/ml, and 
poured in a Petri dish to form 1D 2 mm thick layer. For 
the drug treatment, 1 μl aliquots of a stock solution of 
1 μg/μl cisplatin, 10 μg/μl 5-FU and 0.01  μg/μl epirubicin 
(Sigma-Aldrich, St. Louis, MO) in TE were added to 
10  μg plasmid DNA dissolved in 200  μl TE buffer, and 
the samples were incubated at 37°C for the 6 h. For UV 
treatment, the petri dish was placed on ice and irradiated 
by 1000 J/m2 of UV light. DNA repair capabilities were 
assessed using a host cell reactivation (HCR) assay with 
the pCMVLuc reporter gene plasmid treated by UV or 
anticancer drugs [50]. Briefly, 4 µl (200 ng) of CsCl-
purified pCMVLuc plasmids, damaged or non-damaged, 
were transfected with miR-671-5p overexpressing MDA-
MB-231 cells using Lipofectamine 2000 (Invitrogen). 
human mir-671-5p overexpression and 
microarray analysis
Human miR-671-5p or scrambled mock oligos were 
purchased from LifeTechnologies. Dilutions of 90 pmol 
of miR-671-5p oligos or mocks and 5 μl of Lipofectamine 
2000 (Invitrogen) in Opti-MEM serum-free medium were 
applied to 240,000 cells in a 6-well plate. Total RNA 
from cells with miR-671-5p overexpressing cells were 
converted to cDNA and amplified by Nugen WT Applause 
Plus kit (Nugen). Then the cDNAs were fragmented and 
biotin labeled by the Encode Biotin Module (Nugen) 
before being hybridized to the Affymetrix Exon 1.0 
ST array (Affymetrix). Data were analyzed using the 
GeneSpring GX 12.6.1 (Agilent). Unsupervised clustering 
heat map was generated on the genes with fold change 
> = 1.5 fold and p < = 0.05. 
statistical analysis
miR-671-5p expression in clinical samples was 
analyzed by the exact two-sided binomial test. Data were 
expressed as mean ± standard error (S.E.). Permutation 
tests were performed for MTT assays between control and 
miR-671-5p mimic transfected groups. The student’s t test 
(two tailed) was applied to Matrigel assay between control 
and miR-671-5p transfected group. P-values less than 0.05 
were considered statistically significant. 
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